Ona Therapeutics to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types
Ona Therapeutics, a Spanish biotech company pioneering first-in-class antibody-drug conjugates (ADCs), has appointed key leadership to support its rapid growth and pipeline advancement.
Finding Synergies in Combining ADCs with Multispecific Antibodies
Finding Synergies in Combining ADCs with Multispecific Antibodies
Preclinical Data Highlights the Differentiating Properties of MYTX-011
Preclinical data highlighting the differentiating properties of Mythic Therapeutics' investigational cMET-targeting antibody-drug conjugates (ADC), MYTX-011, published in April 30, 2024 edition of Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR), demonstrated that this novel ADC which leverages Mythic’s innovative FateControl™ technology, actively navigated inside of cells, potentially increasing delivery of anti-cancer agents to tumor cells with less impact on healthy cells.
Merck & Co/MSD and Daiichi Sankyo to Jointly Development and Commercialization Three DXd ADCs
Merck & Co (known as MSD outside of the United States and Canada) and Daiichi Sankyo have entered into a global development and commercialization agreement for the jointly development of three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates. The selected ADCs include patritumab deruxtecan (U3-1402/HER3-DXd), ifinatamab deruxtecan (DS-7300a/I-DXd) and raludotatug deruxtecan (DS-6000a/R-DXd).
Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors Supports Advancement...
Positive top-line data from a recently completed dose-escalation study of BDC-1001 in HER2-expressing solid tumors support the drug to advance into two Phase 2...
BVX001 is Well-tolerated in Preclinical Study – Demonstrating a Favorable Safety Profile Compared with...
Results from a preclinical toxicity evaluation study with BVX001, a novel antibody-drug conjugates (ADC) being developed by BiVictriX, showed positive in vivo data when compared to gemtuzumab ozogamicin (Mylotarg™; Pfizer).
Recent Advances in Antibody-drug Conjugates Produced Using Chemical Conjugation Technology
To date, more than 10 antibody-drug conjugates (ADCs) have been approved by the U.S. Food and Drug Administration (FDA) and contribute to the medical community.
BYON4228 Enhances Anti-tumor Immunity In Vitro
CD47, an immunoglobulin also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on the surface of normal, healthy, hematopoietic stem cells (HSC)...
REGN3124-PBD a Novel EGFRvIII-selective ADC Shows Promise Against Glioblastoma Multiforme Patient-derived Xenografts
Glioblastoma Multiforme (GBM) is a highly aggressive primary malignant brain tumor with few specific molecular targets and poor therapeutic outcomes. The disease accounts for...
Preclinical Study Supports Continued Evaluation of CD25-targeted ADC in Selected Advanced Solid Tumors
Preclinical data for camidanlumab tesirine (formerly ADCT-301; ADC Therapeutics), published in the Journal for ImmunoTherapy of Cancer, the online journal of the Society for...
